293780 — AptaBio Therapeutics Balance Sheet
0.000.00%
- KR₩206bn
- KR₩192bn
- KR₩3bn
Annual balance sheet for AptaBio Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
| 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS/A | Annual Audited Accounts | 
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS | 
| Status: | Final | Final | Final | Final | Final | 
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 42,825 | 22,911 | 16,995 | 51,885 | 31,496 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 680 | 479 | 3,047 | 2,659 | 1,435 | 
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 43,745 | 23,777 | 20,419 | 57,474 | 34,935 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4,889 | 4,822 | 5,848 | 5,129 | 4,962 | 
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 75,444 | 64,911 | 56,114 | 92,519 | 77,434 | 
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 801 | 788 | 1,040 | 818 | 19,540 | 
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 3,403 | 3,246 | 3,744 | 31,156 | 23,237 | 
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 72,040 | 61,665 | 52,370 | 61,363 | 54,197 | 
| Total Liabilities & Shareholders' Equity | 75,444 | 64,911 | 56,114 | 92,519 | 77,434 | 
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |